Ulcerative Colitis (UC): Epidemiology Report and Forecast to 2035

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Ulcerative colitis (UC) is the most common type of inflammatory bowel disease (IBD). Worldwide, the highest number of incident and prevalent cases of UC are reported in Europe and North America (Heydari et al., 2025). UC presents as a chronic disease in which abnormal reactions of the immune system cause inflammation and ulcers on the inner lining of the large intestine, especially the colon and rectum, causing complete damage to the lining (National Institute of Diabetes and Digestive and Kidney Diseases, 2020c). The disease can begin gradually and become worse over time; however, UC can also have an acute onset. Symptoms of UC range from mild to severe, and are similar to other types of IBD, such as Crohn's disease (CD) (Centers for Disease Control and Prevention, 2024). The major risk factors of the disease include genetic factors, immune system reactions, environmental factors, nonsteroidal anti-inflammatory drug (NSAID) use, low levels of antioxidants, diets high in processed food. (National Institute of Diabetes and Digestive and Kidney Diseases, 2020c).

In the 7MM, the diagnosed incident cases of UC are expected to increase from 190,044 cases in 2025 to 194,968 cases in 2035, at an annual growth rate (AGR) of 0.26%. In 2035, the US will have the highest number of diagnosed incident cases of UC in the 7MM, with 112,123 diagnosed incident cases, whereas France will have the fewest diagnosed incident cases with 4,023 cases. In the 7MM, the diagnosed prevalent cases of UC are expected to increase from 2,242,398 cases in 2025 to 2,360,748 cases in 2035, at an AGR of 0.53%. In 2035, the US will have the highest number of diagnosed prevalent cases of UC in the 7MM with 1,032,612 diagnosed prevalent cases, whereas Italy will have the fewest diagnosed prevalent cases with 123,789 cases. GlobalData epidemiologists attribute the changes in the diagnosed incident cases and diagnosed prevalent cases of UC to changing incidence and prevalence rates and population dynamics in each market.

Scope

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for UC in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed incident cases and diagnosed prevalent cases of UC. The diagnosed incident cases of UC are segmented by age (0–14 years, 15–17 years, and 18 years or older in five-year age groups) and sex. The diagnosed prevalent cases of UC are segmented by age (0–14 years, 15–17 years, and 18 years or older in five-year age groups) and sex. The diagnosed prevalent cases of UC in ages 18 years or older are also segmented based on severity in adults. The diagnosed prevalent cases of UC in all ages are segmented based on anti-tumor necrosis factor (anti-TNF) therapy responsiveness (TNF-responding and TNF-non-responding). This epidemiology forecast for UC is supported by data obtained from peer-reviewed articles and population-based studies. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast diagnosed incident cases and diagnosed prevalent cases of UC across markets.

Reasons to Buy

The UC epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global UC market.
  • Quantify patient populations in the global UC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for UC therapeutics in each of the markets covered.

Table of Contents

List of Contents

List of Tables

List of Figures

1 Executive Summary

1.1 Catalyst

1.2 Related reports

1.3 Upcoming reports

2 Epidemiology

2.1 Disease background

2.2 Risk factors and comorbidities

2.3 Global and historical trends

2.4 7MM forecast methodology

2.4.1 Sources

2.4.2 Forecast assumptions and methods

2.4.3 Forecast assumptions and methods: diagnosed incident cases of UC

2.4.4 Forecast assumptions and methods: diagnosed prevalent cases of UC

2.4.5 Diagnosed prevalent cases of UC by severity in adults

2.4.6 Diagnosed prevalent cases of UC by anti-TNF responsiveness

2.5 Epidemiological forecast for UC (2025–35)

2.5.1 Diagnosed incident cases of UC

2.5.2 Age-specific diagnosed incident cases of UC

2.5.3 Sex-specific diagnosed incident cases of UC

2.5.4 Diagnosed prevalent cases of UC

2.5.5 Age-specific diagnosed prevalent cases of UC

2.5.6 Sex-specific diagnosed prevalent cases of UC

2.5.7 Diagnosed prevalent cases of UC by severity in adults

2.5.8 Diagnosed prevalent cases of UC by anti-TNF-responsiveness

2.6 Discussion

2.6.1 Epidemiological forecast insight

2.6.2 Limitations of the analysis

2.6.3 Strengths of the analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Vice President of Disease Intelligence and Epidemiology

3.2.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Contact Us

Table

Table 1: Summary of newly added data types

Table 2: Summary of updated data types

Table 3: Risk factors and comorbidities for UC

Figures

Figure 1: 7MM, diagnosed incident cases of UC, both sexes, N, all ages, 2025 and 2035

Figure 2: 7MM, diagnosed prevalent cases of UC, both sexes, N, all ages, 2025 and 2035

Figure 3: 7MM, diagnosed incidence of UC, men and women, cases per 100,000 population, all ages, 2015–35

Figure 4: 7MM, diagnosed prevalence of UC, men and women, %, all ages, 2015–35

Figure 5: 7MM, sources used to forecast the diagnosed incident cases of UC

Figure 6: 7MM, sources used to forecast the diagnosed prevalent cases of UC

Figure 7: 7MM, sources used to forecast the diagnosed prevalent cases of UC by severity in adults

Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of UC by anti-TNF responsiveness

Figure 9: 7MM, diagnosed incident cases of UC, N, both sexes, all ages, 2025

Figure 10: 7MM, diagnosed incident cases of UC by age, N, both sexes, 2025

Figure 11: 7MM, diagnosed incident cases of UC by sex, N, all ages, 2025

Figure 12: 7MM, diagnosed prevalent cases of UC, N, both sexes, all ages, 2025

Figure 13: 7MM, diagnosed prevalent cases of UC by age, N, both sexes, 2025

Figure 14: 7MM, diagnosed prevalent cases of UC by sex, N, all ages, 2025

Figure 15: 7MM, diagnosed prevalent cases of UC by severity in adults, N, both sexes, ages ≥18 years, 2025

Figure 16: 7MM, diagnosed prevalent cases of UC by anti-TNF responsiveness, N, both sexes, all ages, 2025

Ulcerative Colitis (UC): Epidemiology Report and Forecast to 2035 standard reports
Currency USD
$9,995

Can be used by individual purchaser only

$29,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Ulcerative Colitis (UC): Epidemiology Report and Forecast to 2035 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, September 2026
$2,950 | October 2026
Pharmaceuticals
New
IDWeek 2026: Pre-Conference Coverage
$1,500 | October 2026
Pharmaceuticals
New
Gonorrhea: Market View, Current and Future Competitive Landscape
$3,495 | October 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Ulcerative Colitis (UC): Epidemiology Report and Forecast to 2035 in real time.

  • Access a live Ulcerative Colitis (UC): Epidemiology Report and Forecast to 2035 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.